Loadingβ¦
MARKETS
TOOLS
LEARN
Equiscale Β· Syntellia LLC
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2024
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2024 | $0M | $-179M | $-164M | $-126M | -41.8% | - | 54.2% |
| 2023 | $0M | $-116M | $-106M | $-94M | -25.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 |
|---|---|---|
| Total Revenue | 0 | 0 |
| Operating Revenue | 0 | 0 |
| Operating Expense | 118.46 | 181.10 |
| Research And Development | 97.59 | 152.34 |
| Selling General And Administration | 20.87 | 28.76 |
| Total Expenses | 118.46 | 181.10 |
| Operating Income | -118.46 | -181.10 |
| Total Operating Income As Reported | -118.46 | -181.10 |
| EBITDA | -116.08 | -178.70 |
| Normalized EBITDA | -116.08 | -178.70 |
| EBIT | -118.46 | -181.10 |
| Interest Income | 12.31 | 17.38 |
| Net Interest Income | 12.31 | 17.38 |
| Other Non Operating Income Expenses | 0 | 0.01 |
| Other Income Expense | 0 | 0.01 |
| Interest Income Non Operating | 12.31 | 17.38 |
| Net Non Operating Interest Income Expense | 12.31 | 17.38 |
| Pretax Income | -106.15 | -163.71 |
| Tax Rate For Calcs | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 |
| Net Income Continuous Operations | -106.15 | -163.71 |
| Net Income From Continuing And Discontinued Operation | -106.15 | -163.71 |
| Net Income From Continuing Operation Net Minority Interest | -106.15 | -163.71 |
| Net Income | -106.15 | -163.71 |
| Net Income Common Stockholders | -106.15 | -163.71 |
| Net Income Including Noncontrolling Interests | -106.15 | -163.71 |
| Normalized Income | -106.15 | -163.71 |
| Diluted NI Availto Com Stockholders | -106.15 | -163.71 |
| Basic Average Shares | 34.75 | - |
| Diluted Average Shares | 34.75 | - |
| Reconciled Depreciation | 2.38 | 2.40 |
| General And Administrative Expense | 20.87 | 28.76 |
| Other Gand A | 20.87 | 28.76 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics, Inc.this co. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Zevra Therapeutics, Inc. | ZVRA | $660M | 7.93 | 4.27 | 53.8% | 6.70 |
| SI-BONE, Inc. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Aclaris Therapeutics, Inc. | ACRS |
| $658M |
| -10.13 |
| 6.38 |
| -63.0% |
| - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Beta Bionics, Inc. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Gyre Therapeutics, Inc. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| Peer Median | - | -3.12 | 3.99 | -7.9% | 5.35 | |
Historically, Jul has averaged the highest return (+118.9%); May the lowest (-31.4%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | β | β | β | β | -31.4%Negative MonthMay 2026: -31.41% | +26.1%Positive MonthJun 2026: +26.07% | +118.9%Positive MonthJul 2026: +118.89% | +3.3%*Positive MonthAug 2026: +3.32% | β | β | β | β |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 1 year of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
